Stelara 90MG/ML SYR 1S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTEQ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,752
Award facts
- Contract value 100% obligated
- $49,752.39 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $49,752.39 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of STELARA 90MG/ML syringes. This firm fixed-price delivery order, issued on December 9, 2025, with an ultimate completion date of December 18, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors for supplying pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through the DLA's Medical Supply Chain division. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, supporting recurring medical supply needs of military healthcare facilities globally. The underlying PPV-G GEN V contract, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, structured with a 30-month base period and three 30-month option periods to ensure sustained pharmaceutical support for Department of Defense operations.
Quick answers
Who was awarded contract SPE2DR26FBTEQ?
SPE2DR26FBTEQ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 9, 2025.
How much is contract SPE2DR26FBTEQ worth?
The government has obligated $49,752 on SPE2DR26FBTEQ.
Is contract SPE2DR26FBTEQ an order under another contract?
Yes. SPE2DR26FBTEQ is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTEQ competed?
The extent of competition for SPE2DR26FBTEQ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award